Breaking News

Absci Expands in Europe, Adds Senior Leadership in Switzerland

The generative AI drug company ramps up its internal pipeline and R&D portfolio, tapping into European markets, talent, and tech.

Absci Corporation, a generative AI drug creation company, is expanding into the European pharmaceutical market with the opening of an Innovation Center in Zug, Switzerland. The Zug Innovation Center brings Absci’s AI drug creation platform to the global stage and taps into the European pharma and biotech ecosystem. Absci welcomed two senior executives to lead its drug creation team: Christine Lemke, SVP of Portfolio & Growth Strategy, and Christian Stegmann, SVP of Drug Creation. “A...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters